NVIDIA and Novo Nordisk Partner to Accelerate AI-Driven Drug Discovery
NVIDIA; Novo Nordisk; AI models; drug discovery; Gefion AI Supercomputer; BioNeMo; Omniverse; pharmaceutical innovation
Genentech Lays Off 143 Employees as Part of Ongoing Cuts by Roche in Bay Area
Genentech; Roche; layoffs; South San Francisco; biotech job cuts; Bay Area; AI strategy; WARN filing; pharmaceutical; biotech industry
FDA Leaders Anticipate Imminent Drug Approval Decisions
FDA; drug approval; PDUFA date; regulatory decision; upcoming approvals; FDA leadership
Novo Nordisk Signs $812M Deal with Deep Apple to Develop Non-Incretin Obesity Drugs
Novo Nordisk; Deep Apple Therapeutics; obesity; non-incretin; GPCR; cardiometabolic disease; small molecules; research collaboration; deal; drug discovery
Novo Nordisk Strikes Major Deal with Deep Apple Therapeutics for Oral Cardiometabolic Medicines
Novo Nordisk; Deep Apple Therapeutics; cardiometabolic diseases; oral medicines; obesity; small molecule therapeutics; GPCR target; R&D collaboration; biotech partnership
Organoid Startup Raises $21M to Test Drugs and Vaccines in Human Lymph Nodes-in-a-Dish
organoids; lymph nodes; drug testing; vaccine testing; biotech startup; research funding; human tissue models
Best Practice Customer-Facing Organization Study Report (2025) – Key Findings and Trends
customer-facing organization; best practices; 2025 report; customer experience; self-service; AI integration; CX optimization; digital transformation
Eli Lilly Strikes $650M Deal with Juvena to Develop Muscle-Boosting Drugs
Eli Lilly; Juvena Therapeutics; muscle-boosting drugs; AI drug discovery; muscle health; biotech collaboration; stem cell secreted proteins; drug development; obesity management; $650 million deal
Merck Wins FDA Approval for RSV Antibody Drug, Intensifying Market Competition
Merck; FDA approval; RSV; monoclonal antibody; infants; Enflonsia; competitive market; Sanofi; AstraZeneca
FDA Reinstates Generic Drug Policy Group After April Firings
FDA; generic drugs; policy office; Division of Policy Development; reinstatement; layoffs; drug prices; administrative leave